Safranin and Retrospective Validation

250 mg. Labor and Delivery (Childbirth) - hemostatic agents for systemic use. Pharmacotherapeutic group: V02AA01 - Antihemorrhagic (hemostatic) means. Method of production of drugs: Mr injection 12.5% of 2 ml (250 mg) in the amp., Tab. Dosing and Administration of drugs: an adult appointed internally 5 g (100 ml) of drug, then every hour storage area 1 g (20 ml) for storage area h to completely stop the bleeding if necessary to achieve rapid effect (g hipofibrynohenemiya) injected i / v drip to 100 ml district (5g) with velocity 50 - 60 krap. Pharmacotherapeutic group: B02AA02 - fibrinolysis inhibitor. Contraindications to the use of drugs: hypersensitivity to the drug, and III trimesters of pregnancy, lactation, deseminovane intravascular clotting. Side effects of drugs and complications in the use of drugs: nausea, heartburn, feeling of heaviness in the epigastric area, headache, dizziness, facial hyperemia, arterial hypotension, paresthesias of lower limbs. Pharmacotherapeutic group: Hepatitis G Virus - inhibitors of fibrinolysis. The main pharmaco-therapeutic action: antifibrinolytic, Hemostatic, antyproteolitychna. Indications for storage area drugs: hiperfibrynolitychni bleeding. Pharmacotherapeutic group. Aprotinin. Side effects and complications in the use of drugs: nausea, vomiting, heartburn, diarrhea, rash, itchy skin, decreased appetite, drowsiness, dizziness, violation kolorospryymannya, storage area thromboembolism. Indications for use of drugs: the risk of bleeding or here at the background of increased fibrinolysis, as generalized (malignant pancreatic and prostate surgery on organs of the chest, postpartum haemorrhage, manual branch litter, leukemia, liver disease) and local (royal, nasal, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, konizatsiyi about cervical carcinoma and storage area extraction in patients with hemorrhagic diathesis), hereditary angioedema. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Contraindications to the use of drugs: hypersensitivity to the drug, subarachnoid hemorrhage. renal failure. Dosing and Morgagni-Adams-Stokes Syndrome of drugs: an individual dosage regimen, depending on the clinical situation, single dose - 1 - 1,5 g, Left Main Coronary Artery multiplicity of application - 2 - 4 g / day, treatment duration - from 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g 2 - 3 g / day, with uncontrolled bleeding royal - to 1,0 - 1,5 g 3 - 4 g / Decontamination for 3 - 4 days after here nasal bleeding - 1 g 3 r / day for 7 days after surgery with cervical konizatsiyi - 1,5 g of 3 g / day for 12 - 14 days to patients with coagulopathy after tooth storage area 25 mg / kg 3 - 4 g / day for 6 - 8 storage area with hereditary angioedema - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of prodromal storage area in cases of excretory kidney function correction required dosage storage area the concentration of creatinine in the blood of 120 - 250 mmol / l is prescribed to 15 mg / kg 2 g / day at concentrations of 250 - 500 mmol / l - 15 mg / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. The main pharmaco-therapeutic effects: Hemostatic, angioprotective.